MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of ...

Hims & Hers is evolving beyond its original focus, aggressively expanding into peptides and GLP-1. Read why I reiterate my ...

Semaglutide, a synthetic analog of glucagon-like peptide-1 (GLP-1), has garnered attention for its intriguing properties and potential implications in various r ...

Canada: A recent observational cohort study from Canada revealed that older diabetic patients taking GLP-1 receptor ...

Biodexa Pharmaceuticals ( ($BDRX) ) just unveiled an announcement. On June 4, 2025, Biodexa Pharmaceuticals announced the recruitment of the first ...

Among older patients with diabetes, glucagon-like peptide 1 receptor agonists were associated with an increased risk for ...

For patients with diabetes, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased ...

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes Biodexa Pharmaceuticals PLC ...

Increased consumption of phytosterols reduced the risk for CVD and type 2 diabetes, a study presented at the annual NUTRITION ...

This recent study introduces a non–insulin-specific version of the Diabetes Eating Problem Survey–Revised tool that screens ...

Wenzhou Medical University researchers have reimagined the spleen as a viable site for islet transplantation, enabling long-term diabetes control without the burden of full immunosuppression.